Background: During the future Moon and Mars missions, astronauts will be exposed to space radiation (IR) for extended time. The majority of space flight-associated risks identified for the cardiovascular (CV) system to date were determined shortly after low Earth orbit (LEO) short-and long-duration space flights that include: serious cardiac dysrhythmias, compromised orthostatic CV response and manifestation of previously asymptomatic CV disease. Further ground-based experiments using a surrogate model of microgravity supported the space flight data for significant cardiac remodeling due to prolonged exposure to microgravity. These symptoms were determined to be a consequence of adaptation to microgravity that could be ameliorated by a post-mission exercise program, and were not identified as risk factors that were causatively related to space IR. Long-term degenerative effects of cosmic IR during and after space flights on CV system are unknown.
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It was suggested that due to GCR, each cell in an astronaut's body will be traversed by 1 H every 3 days, helium ( 2 He) nuclei every few weeks and high charge and energy (HZE) nuclei (e.g.
28
Si, 56 Fe) every few months. Despite the fact that only 1% of GCR is composed of ions heavier than helium,~41% of the IR dose-equivalent is predicted to be HZE particles with 13% being from 56 Fe particles, only. During an exploration-class space mission to Mars, astronauts will not have access to comprehensive healthcare services for a period of at least 2-3 years. Since the majority of experienced astronauts are middle-aged (average age is 46, and the range is 33-58 years), they are at risk for developing serious CV events which could be lifethreatening for the astronaut and mission-threatening for NASA. Therefore, it is important to evaluate the effects and potential CV risks caused by space IR. We hypothesized that: (i) low-dose space IR-induced biological responses may be long-lasting and are IR type-dependent; (ii) IR may increase CV risks in the aging heart (IR + AGING model) and affect the heart recovery after an adverse CV event, such as acute myocardial infarct (IR + AGING + AMI model).
Methods: Eight-to 9-month-old C57BL/6N male mice were IR once with proton ( 1 H) 50 cGy, 1 GeV/n or iron ( 56 Fe) 15 cGy, 1 GeV/n. We evaluated IR-induced biological tissue responses-underlying molecular mechanisms, calcium handling, signal transduction, gene expression and cardiac fibrosis. Cardiac function was assessed by echocardiography (ECHO) and hemodynamic measurements (HEMO) as detailed in Fig. 1 . AMI was induced by ligation of left anterior descending coronary artery 1 and 3 months post-IR as detailed in Fig. 2 Fe-IR may arise from the excessive demand on the heart due to prolonged activation of compensatory mechanisms that lead to changes in SERCA2a and p-Creb1 levels. This may represent a possible intracellular mechanism of heart failure in development in 56 Fe-IR hearts. In the IR + AGING + AMI model, no mortality was observed among three different groups 1 or 3 months post-IR and up to 28 days post-AMI. However, 1 month post-IR and 28 days post-AMI, the infarct size was significantly smaller in 56 Fe-IR ( p < 0.003) and 1 H-IR ( p = n.s.) vs control-IR mice, suggesting that at 1 month,
56
Fe-IR primes the heart to recover better after AMI. In contrast, 3 months post AMI, 1 H-AMI mice had a better cardiac functional recovery compared with control-AMI and 56 Fe-AMI mice. The ejection fraction (EF%) was most decreased in 56 Fe-AMI mice ( 56 Fe-AMI vs 1 H-AMI: 18 vs 48%, P < 0.007,~65-70% pre-AMI EF% for all groups). There was a 2-to 4-fold increase in LVEDP in 56 Fe-AMI vs 1 H-AMI (P < 0.04), suggesting that 56 Fe-AMI hearts developed cardiac de-compensation. Western blots showed that 3 days post-AMI, compared with control-and 1 H-IR-AMI mice,
Fe-IR-AMI hearts had a 4-to 7-fold (P < 0.04) decreases in p-Akt (Thr308), p-Erk1/2 (P < 0.007) and~2-fold (P < 0.01) increase in phosphorylated ribosomal protein S6 kinase ( p-S6k, a readout for mTORC1 pathway activation), suggesting decreased survival and angiogenesis signaling and decreased autophagy in these hearts. Seven days post-AMI, the levels of p-pErk1/2 were comparable between all three treatment conditions. However, in 56 Fe-IR-AMI hearts, the p-Akt (Thr308) levels remained 4-fold decreased. Additionally, here was a 3-fold (P<0.05) decrease in p-S6k levels and >10-fold increase in p-p38 MAPK level in 56 Fe vs control and 1 H-IR-AMI hearts, suggesting continuous decreases in the survival, proliferation and angiogenesis signaling ( p-Akt and p-S6k) and increase in the apoptotic signaling ( p-p38 MAPK) up to Day 7 post-AMI in 56 Fe-IR-AMI mice.
In summary, our results revealed that by 1 and 3 months post-IR in IR + AGING, 56 Fe-IR but not 1 H-IR mice had worse cardiac function. Further, a single 1 H-IR 3 months prior to AMI improved, whereas 56
Fe-IR worsened, recovery 
